Unlocking The Potential Applications of A2ML1: A Novel Protein Isoform

Target Name: A2ML1

NCBI ID: G144568

A2ML1

Unlocking The Potential Applications of A2ML1: A Novel Protein Isoform

Unraveling the Potential Applications of A2ML1: A novel protein Isoform with Promising Potential as a Drug Target or Biomarker

Abstract:

Alpha-2-macroglobulin-like protein 1 (A2ML1) is a novel protein isoform that has been identified as a promising drug target or biomarker. It is expressed in various tissues and plays a crucial role in various cellular processes. In this article, we will discuss the characterization of A2ML1, its potential applications as a drug target or biomarker, and the ongoing research in this field.

Introduction:

Alpha-2-macroglobulin-like protein 1 (A2ML1) is a member of the A2ML family, which is characterized by the presence of a unique N-terminal hypervariable region (HVR) and a C-terminal conserved domain (CTD). A2ML1 is expressed in various tissues, including liver, spleen, and bone marrow, and has been implicated in various cellular processes, including cell adhesion, migration, and invasion.

Expression and Localization:

A2ML1 is a cytoplasmic protein that is mainly expressed in the cytoplasm of various cell types. It is mainly localized to the periplasmic space, where it can interact with various cellular signaling pathways, including the TGF-灏? pathway.

Function and Potential Applications:

A2ML1 has been shown to play a crucial role in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to mediate the formation of tight junctions in epithelial cells, which are important for cell-cell communication and tissue repair ( 3).

A2ML1 has also been shown to be involved in the regulation of cell apoptosis. In various cellular models, A2ML1 has been shown to induce cell apoptosis, which may be a potential mechanism underlying its therapeutic potential as a drug target.

In addition to its role in cellular processes, A2ML1 has also been shown to have potential applications as a drug target or biomarker. Its unique HVR and CTD have been targeted by various researchers, who have shown that A2ML1 can be effectively modified to alter its stability , localization, and interactions with various drug molecules.

Drug Target Potential:

A2ML1 has been shown to be a potential drug target due to its unique HVR and CTD, which make it vulnerable to small molecules. Several studies have shown that various small molecules can interact with A2ML1 and alter its stability, localization, and interactions with various signaling pathways.

One of the most promising small molecules for targeting A2ML1 is the drug A-241832, which is a potent inhibitor of A2ML1-CTD interactions and has been shown to induce cell apoptosis in various cellular models.

Biomarker Potential:

A2ML1 has also been shown to have potential as a biomarker in various diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, lung, and colorectal cancer.

In addition to its potential as a biomarker, A2ML1 has also been shown to be involved in the regulation of cancer cell survival. Several studies have shown that A2ML1 can inhibit the progression of cancer cell proliferation and migration.

Conclusion:

In conclusion, A2ML1 is a novel protein isoform that has been identified as a promising drug target or biomarker. Its unique HVR and CTD make it vulnerable to small molecules, and its expression has been shown to play a crucial role in various cellular processes. Further research is needed to fully understand its potential applications as a drug target or biomarker.

Protein Name: Alpha-2-macroglobulin Like 1

Functions: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase (By similarity). Displays inhibitory activity against chymotrypsin, papain, thermolysin, subtilisin A and, to a lesser extent, elastase but not trypsin. May play an important role during desquamation by inhibiting extracellular proteases

The "A2ML1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about A2ML1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets